CSL Seqirus

CSL’s Opening And Closing Doors Near the end of fourth-quarter 2024 earnings season for life science companies, Australia’s CSL reported its half-year results. Its stock price initially increased by a

A misinformation dispute in Japan over Arcturus Therapeutics' COVID-19 vaccine Kostaive (ARCT-154) saw an unprecedented twist in December, when local distributor Meiji Seika Pharma decided to pursue

The European Medicines Agency is set to decide this week on whether to recommend EU marketing approval for a number of new products, including three orphan medicines. A decision is expected on Bridge

It fell to Bayer AG and CSL Limited to wrap up the big pharma earnings season. They faced a less desirable shared challenge – lingering impacts from past deals. Quarterly Results Opacity In report